drugset / Trial / NCT06613698

A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease

NCT06613698 ↗

Phase 2 Recruiting 393 enrolled GlaxoSmithKline
NaSequentialDouble-blindTreatment

Summary

The goal of this study is to assess the safety and efficacy of GSK4532990 in participants with alcohol-related liver disease.

Timeline

Start
2024-09-27
Primary completion
2027-08-02
Completion
2028-03-07

Drugs

EvaluationDrugModalityDoseRoute
Subject GSK4532990 Unknown — —